Edition:
India

Taro Pharmaceutical Industries Ltd (TARO.N)

TARO.N on New York Stock Exchange

117.75USD
23 Sep 2016
Change (% chg)

$0.95 (+0.81%)
Prev Close
$116.80
Open
$116.13
Day's High
$118.10
Day's Low
$116.05
Volume
32,216
Avg. Vol
39,415
52-wk High
$157.84
52-wk Low
$114.35

TARO.N

Chart for TARO.N

About

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $5,035.69
Shares Outstanding(Mil.): 42.77
Dividend: --
Yield (%): --

Financials

  TARO.N Industry Sector
P/E (TTM): 9.32 36.61 36.60
EPS (TTM): 12.63 -- --
ROI: 32.25 14.46 13.91
ROE: 32.38 15.26 14.82

U.S. Justice Department subpoenas Taro over generic drug pricing

WASHINGTON Taro Pharmaceutical Industries Ltd and two of its senior officers received grand jury subpoenas last week in connection with a federal antitrust investigation into generic drug pricing, the company disclosed.

12 Sep 2016

UPDATE 1-U.S. Justice Department subpoenas Taro over generic drug pricing

WASHINGTON, Sept 11 Taro Pharmaceutical Industries Ltd and two of its senior officers received grand jury subpoenas last week in connection with a federal antitrust investigation into generic drug pricing, the company disclosed.

12 Sep 2016

BRIEF-Taro posts qtrly earnings per share $2.59

* Quarterly earnings per share $2.59 Source text for Eikon: Further company coverage:

11 Aug 2016

BRIEF-Taro Pharma CEO Kal Sundaram to return to Sun Pharma headquarters by the end of 2016

* Taro ceo Kal Sundaram to return to Sun Pharma headquarters by the end of 2016

07 Jul 2016

BRIEF-Amarin appoints Michael Kalb chief financial officer

* Kalb joins Amarin from Taro Pharmaceutical Industries Ltd Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

30 Jun 2016

BRIEF-Taro pharmaceutical industries Q4 shr $2.68

* Qtrly net sales of $265.1 million, increased $20.9 million, or 8.6%, on relatively flat volumes

27 May 2016

Earnings vs. Estimates